

## Synthesis, Characterization and Antimicrobial Activity of *N*-Pyridin-3-yl-benzenesulfonamide

A.O. Ijuomah, D.C. Ike and M.C. Obi

Department of Chemistry, College of Physical Sciences, Joseph Sarwuan Tarka University Makurdi, Benue State, Nigeria

### Abstract

This study describes a simple one-pot synthesis of *N*-pyridin-3-yl-benzenesulfonamide and its antimicrobial activity. The reaction of benzene sulfonyl chloride with 3-aminopyridine in the presence of aqueous Na<sub>2</sub>CO<sub>3</sub> and HCl as a scavenger furnished the sulfonamide in 93.3% yield. The structure of the synthesized compound was established using the spectral data obtained from FTIR, <sup>1</sup>HNMR and <sup>13</sup>CNMR). All spectrometric spectrum bands and peaks obtained were sulfonamide-related. The antibacterial test carried out against Gram-positive bacterium (*Staphylococcus aureus*) and Gram-negative bacteria (*Salmonella typhi* and *Escherichia coli*) tested upon at concentrations 150, 100, 50 and 25 mg/ml revealed that the synthesized *N*-pyridin-3-yl-benzenesulfonamide possesses great antimicrobial activity.

### 1.0 Introduction

Sulfonamides, compounds with a general structural formula RSO<sub>2</sub>NHR' where R' could H any organic group represents a very important group of compounds in both synthetic and medicinal chemistry [1]. Sulphonamides commonly referred to by many as 'sulfa drug' were the first therapeutic agents extensively used directly or indirectly as preventive and chemotherapeutic drugs against numerous diseases [1]. A large number of drugs with the sulfonamide moiety are already in wide clinical use; as antihypertensive agents [2], antibacterial [3], antiprotozoal [4], antifungal [5], anti-inflammatory [6], nonpeptidic vasopressin receptor antagonists [7] and translation initiation inhibitors [8]. Furthermore, other vital sulphonamide derivatives have been used as carbonic anhydrase

Received: June 23, 2022; Accepted: July 1, 2022

Keywords and phrases: *N*-pyridin-3-yl-benzenesulfonamide; antimicrobial activity; synthesis; sulfonamide and 3-aminopyridine.

Copyright © 2022 the authors. This is an open access article distributed under the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

inhibitors of commercial importance [9], and are also effective for the treatment of urinary, intestinal and ophthalmic infections, scalds, ulcerative colitis [2], rheumatoid arthritis [2,10], male erectile dysfunction as the phosphodiesterase-5inhibitor Sildenafil – better known under its commercial name, Viagra [2,11], and obesity [12]. More recently, sulphonamides have been employed as an anticancer agent [13], as the antiviral HIV protease inhibitor amprenavir and in Alzheimer's disease [2].

The discovery and formulation of the first Sulphonamide drug (Prontosil), unlocked a new age in medicine. This compound was first synthesized by Bayer chemists Josef Klarer and Fritz Mietzsch [14] as part of a research program initially designed for the synthesis of dyes with biological activities. The molecule was tested and in the late equinox of 1932 was found to be very effective in the treatment of some bacterial infections in mice by Gerhard Domagk, who in turn received the Nobel Prize in Medicine in 1939 [14]. A survey carried out in 2016 revealed that sulphonamides represented 15% of the top 100 most recommended drugs [14] for the therapeutic applications against cardiovascular, infectious, and neurological diseases [14]. In the agrochemical industry also, the sulphonamide motifs are incorporated in a variety of pesticides, including Asulam, Orzalin, Fomesafen, Halosafen, and Sulfentrazone [14].

There are various developed synthetic pathways to the production of Sulphonamides and its derivatives. The most common of them is the reaction of sulfonyl chloride and amine. This article reports the synthesis of *N*-pyridin-3-yl-benzenesulfonamide by reaction of the benzene sulphonyl chloride and the corresponding 3-aminopyridine, the characterization of the synthesized compound using FTIR and NMR spectrophotometry analysis and finally the evaluation of the antimicrobial activity of the synthesized compound.

## 2.0 Materials and Method


### 2.1 General

Chemicals used in this study were commercially analytical grade and were used as received. Chemicals used includes; 3-aminopyridine (JHD, 99.8%), Benzenesulphonyl chloride (BHD, 99%), Dimethylsulfoxide (BHD, 99%), Concentrated hydrochloric acid (JHD, 37%), Sodium trioxocarbonate (IV) (lubachemie 99%), Ethanol (JHD, 99%). Nuclear Magnetic Resonance (NMR) analysis of the compound was carried out using a JEOL-LA-400MHz NMR spectrophotometer with  $\text{CDCl}_3$  used as internal standard at the University of Strathclyde. Fourier Transform Infrared Spectroscopy (FT-IR) analysis was

carried out using 8400SINFRARED Spectrophotometer, by employing KBr discs at NARIT Zaria.

## 2.2 Synthesis of *N*-Pyridin-3-yl-benzenesulfonamide

The procedure reported by Almarhoon *et al.* [15] with slight modification was adopted. A mixture of 3-aminopyridine (3.0 g, 0.032 mol) and benzene sulphonylchloride (3.0 mL, 0.032 mol) was gently introduced into a round bottom flask containing (25.0 mL, 2.0 M)  $\text{Na}_2\text{CO}_3$  aqueous solution and stirred for 2 hours. The pH of the reaction was closely monitored and maintained at a high value of 8 – 10. At the end of the reaction, (2.0 M, 25.0 mL) HCl was slowly added to the reaction mixture to adjusted the pH to 2. The reaction mixture was then filtered to obtain the brown precipitates which were formed (Scheme 1). This crude product was washed repeatedly with distilled water and finally recrystallized from hot ethanol. The percentage yield was thus calculated using equation 1 and the melting point determined using a melting point apparatus (Sciencetech SE-175).



**Scheme 1.** Synthetic pathway for *N*-pyridin-3-yl-benzenesulfonamide.

## 2.3 Characterization

The purified white crystals were subjected to both  $^1\text{H}$ NMR and  $^{13}\text{C}$ NMR spectroscopy using a JEOL-LA-400MHz NMR spectrophotometer with DMSO as internal standard at the University of Strathclyde. Fourier Transform Infrared Spectroscopy (FT-IR) analysis using FTIR-8400SINFRARED Spectrophotometer, employing a KBr discs at NARIT Zaria.

## 2.4 Antimicrobial screening


The antimicrobial screening of the synthesized compound and Ciprofloxacin (as control) were carried out using the well in agar (well diffusion) method as reported by Ike

*et al.* [16]. The already characterized gram positive bacterium (*Staphylococcus aureus*) and two-gram negative bacteria (*Salmonella typhi* and *Escherichia coli*) were resuscitated using selective mediums such as Tyrosine methylene blue agar (for *E.coli*) and nutrient agar (for others). Various concentrations (150-25 mg/ml) of the synthesized compound were prepared following the report of Akujobi *et al.* [17] and Ike *et al.* [16] using 30% Dimethylsulfoxide (DMSO). In order to achieve standard and uniformity in inoculation of the bacteria species, the McFarland standard was also prepared.

### 3.0 Results and Discussion

#### 3.1 Results

**Table1.** Physicochemical characterization of synthesized compound.

Properties	Values
Name	<i>N</i> -Pyridin-3-yl-benzenesulfonamide
Appearance	Light brown crystalline solid
Molecular mass	234.273g/mol
yield	2.8g, 93.3 %
Melting point	160-162°C
Structure	

**Table 2.** FTIR absorption bands of synthesized compound.

S/N	Functional group	Vibration frequency (cm <sup>-1</sup> )	
		Sample	*Ref Values
1	N-H	3664.67	3350 – 3310
2	C=C	1481.32, 1519.96& 1573.97	1650 – 1566
3	C-N	1026.16	1250 – 1020
4	C=N	1651.12	1690 – 1640
5	S=O	1350.22	1370 – 1335
6	C-H	3009.05 &2877.89	3000-2500

\*Source: utsc.utorinto.ca

**Table 3.**  $^1\text{H}$ NMR signals of the synthesized compound.


Positions	Experimental	ChemDraw software analysis
	126 MHz, DMSO, ( $\delta$ ppm)	DMSO, ( $\delta$ ppm)
1	7.61 (d, 1H, -CH)	7.26 (d, 1H, -CH)
3	7.83 (s, 1H, -CH)	8.53 (d, 1H, -CH)
4	7.63 (d, 1H, -CH)	8.23 (d, 1H, -CH)
5	7.50 (t, 1H, -CH)	7.40 (t, 1H, -CH)
7	8.29 (s, 1H, -NH)	4.00 (s, 1H, -NH)
10 & 14	7.55 (d, 1H, -CH)	7.93 (d, 1H, -CH)
11 & 13	7.29 (t, 1H, -CH)	7.54 (t, 1H, -CH)
12	7.78 (t, 1H, -CH)	7.30 (t, 1H, -CH)


**Table 4.**  $^{13}\text{C}$ NMR signals of the synthesized compound

Positions	Experimental	ChemDraw software analysis
	126 MHz, DMSO, ( $\delta$ ppm)	DMSO, ( $\delta$ ppm)
1	145.23 (- <u>C</u> =N)	137.90 (- <u>C</u> =N)
3	141.66 (C- <u>C</u> -N)	139.00 (C- <u>C</u> -N)
4	124.02 (- <u>C</u> -CH)	124.50 (- <u>C</u> -CH)
5	127.51 (-C- <u>C</u> -CH)	121.50 (-C- <u>C</u> -CH)
6	129.41 (- <u>C</u> -NH)	145.10 (- <u>C</u> -NH)
9	139.02 (- <u>C</u> -S)	139.30 (- <u>C</u> -S)
10 & 14	128.05 (- <u>C</u> -C-S)	125.50 (- <u>C</u> -C-S)
11 & 13	129.41(CH- <u>C</u> -CH)	128.80(CH- <u>C</u> -CH)
12	133.19 (CH- <u>C</u> -CH)	131.70 (CH- <u>C</u> -CH)


**Table 5.** Antimicrobial activity of *N*-pyridin-3-yl-benzenesulfonamide and ciprofloxacin.

Sample	Concentration (ppm)	Average zone of inhibition (mm)		
		Gram negative bacteria		Gram positive bacteria
		<i>E. coli</i>	<i>S.typhi</i>	<i>S.aureus</i>
<i>N</i> -pyridin-3-yl- benzenesulfonamide	150	12	16	14
	100	8	12	10
	50	-	8	5
	25	-	5	-
Ciprofloxacin (control)	150	16	26	32
	100	12	24	28
	50	8	18	22
	25	-	16	18


**Figure 1.** Numbered structure of *N*-pyridin-3-yl-benzenesulfonamide.



**Figure 2.** FTIR spectrum of *N*-pyridin-3yl-benzenesulfonamide.



**Figure 3.** <sup>1</sup>H NMR spectrum of *N*-pyridin-3yl-benzenesulfonamide.



**Figure 4.**  $^{13}\text{C}$  NMR spectrum of *N*-pyridin-3-yl-benzenesulfonamide.

### 3.2 Discussion

*N*-Pyridin-3-yl-benzenesulfonamide, a light brown crystalline solid was synthesized in the presence of  $\text{Na}_2\text{CO}_3$  by a facile one-pot reaction of 3-aminopyridine with benzene sulfonyl chloride. It was produced at a high yield of 93.3 %, which is consistent with the findings of Ijeomah *et al.* [1].

The melting temperature of the synthesized compound was also found to be between  $160 - 162^\circ\text{C}$  (Table 1) using a melting point apparatus. The synthesised product was also subjected to FTIR analysis, and the spectrum data obtained (Figure 2, Table 2) revealed a characteristic absorption band at  $1350.22\text{ cm}^{-1}$ , which corresponds to a sulphonamide's  $\text{S}=\text{O}$  stretch vibration,  $1026.16\text{ cm}^{-1}$ , which reveals a  $\text{C}-\text{N}$  aromatic amine stretch vibration,  $1651.12\text{ cm}^{-1}$ , which corresponds to an aromatic compound's  $\text{C}=\text{N}$  stretch vibration. The only one band at  $3664.67\text{ cm}^{-1}$  which corresponds to  $\text{N}-\text{H}$  stretch vibration showed that the product is a secondary amine and  $3009.05\text{ cm}^{-1}$  corresponding to the  $\text{C}-\text{H}$  stretch vibrations of the aromatics.

The  $^1\text{H}$ NMR spectra of the synthesised compound (Figure 3, Table 3) revealed a singlet peak at 7.88 and 8.29 respectively for the  $\text{NH}$  proton and the  $\text{N}-\text{C}-\text{CH}=\text{N}$  (positions 3 and 8 respectively). Doublet peaks were observed at 7.55, 7.61 and 7.63 corresponding to the  $\text{CH}$  protons at positions 10 & 14, 1 and 4 respectively (Figure 1).



Triplet peaks at 7.29, 7.50 and 7.78 were also observed for the  $\text{CH}$  protons at positions 11 & 13, 5 and 12 respectively (Figure 1).

$^{13}\text{C}$ NMR spectra (Figure 4, Table 4) revealed peaks at 145.23, 141.66, 124.02, 127.51, 129.41, 139.02, 128.05, 129.41 and 133.19 ppm which corresponds to carbon atoms at positions 1, 3, 4, 5, 6, 9, 10 & 14, 11 & 13 and 12 respectively (Figure 1). Both the  $^1\text{H}$  and  $^{13}\text{C}$ NMR spectrum findings are consistent with prior observations [1,10-11].

The result (Table 5) of the biological activity of the synthesized N-pyridin-3yl-benzenesulfonamide against gram-positive bacterium (*Staphylococcus aureus*) and gram-negative bacteria (*Salmonella typhi* and *Escherichia coli*) tested upon at concentrations 150, 100, 50 and 25 mg/ml revealed that the synthesized N-pyridin-3yl-benzenesulfonamide possesses great antimicrobial activity against all tried bacteria. The highest antibacterial activity was observed against *Salmonella typhi* at a concentration of 150 – 25 mg/ml which gave an average inhibiting zone of 16, 12, 8, and 5 mm respectively. Average inhibiting zones of 14, 10 and 5 mm at concentrations 150, 100 and 50 mg/ml respectively was observed when tried against *Staphylococcus aureus*. No average zone of inhibition was seen for concentration 25 mg/ml. The weakest antibacterial activity was observed against *Escherichia coli*, with poor average zones of inhibitions of 12 and 8 mm observed at concentrations 150 and 100 mg/ml respectively. Whereas, no average zone of inhibition was observed at concentrations 50 and 25 mg/ml.

#### 4.0 Conclusion

The sulfonamide, N-pyridin-3yl-benzenesulfonamide was successfully synthesized and characterised using the spectral data obtained from FTIR,  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectroscopic analyses. The results obtained showed peaks similar to the ones in literature for sulfonamides. This synthesized compound also show great potential as a possible candidate for future antimicrobial agent as revealed by the result of the antimicrobial screening carried out. Also, the easy synthetic route and the high yield of N-pyridin-3yl-benzenesulfonamide makes it an attractive alternative to pharmaceutical industries seeking new lead compounds.

#### References

- [1] Ijeomah, A.O., Ike, D.C., & Odoh, J.O. (2021). One pot facile synthesis and characterization of 2-(phenyl-2-sulfonylamino)-6-methylpyridine. *FUAM Journal of Pure and Applied Science*, 1(2), 84-88.

- [2] Kołaczek, A., Fusiarz, I., Ławecka, J., & Branowska, D. (2014). Biological activity and synthesis of sulfonamide derivatives: a brief review. *Chemik*, 68(7), 620-628.
- [3] Kanda, Y., Kawanishi, Y., Oda, K., Sakata, T., Mihara, S. I., Asakura, K., & Konoike, T. (2001). Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists. *Bioorganic & Medicinal Chemistry*, 9(4), 897-907. [https://doi.org/10.1016/S0968-0896\(00\)00305-9](https://doi.org/10.1016/S0968-0896(00)00305-9)
- [4] Mermer, A., Demirbas, N., Uslu, H., Demirbas, A., Ceylan, S., & Sirin, Y. (2019). Synthesis of novel Schiff bases using green chemistry techniques; antimicrobial, antioxidant, antiurease activity screening and molecular docking studies. *Journal of Molecular Structure*, 1181, 412-422. <https://doi.org/10.1016/j.molstruc.2018.12.114>
- [5] Chibale, K., Haupt, H., Kendrick, H., Yardley, V., Saravanamuthu, A., Fairlamb, A.H., & Croft, S.L. (2001). Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine. *Bioorganic & Medicinal Chemistry Letters*, 11(19), 2655-2657. [https://doi.org/10.1016/S0960-894X\(01\)00528-5](https://doi.org/10.1016/S0960-894X(01)00528-5)
- [6] Kavitha, C., Narendra, K., Ratnakar, A., Poojith, N., Sampath, C., Banik, S., & Naidu, N.V. (2020). An analysis of structural, spectroscopic signatures, reactivity and anti-bacterial study of synthesized 4-chloro-3-sulfamoylbenzoic acid. *Journal of Molecular Structure*, 1202, 127176. <https://doi.org/10.1016/j.molstruc.2019.127176>
- [7] Alaa, A.M., Angeli, A., El-Azab, A.S., Hammouda, M.E., El-Sherbeny, M.A., & Supuran, C.T. (2019). Synthesis and anti-inflammatory activity of sulfonamides and carboxylates incorporating trimellitimides: dual cyclooxygenase/carbonic anhydrase inhibitory actions. *Bioorganic Chemistry*, 84, 260-268. <https://doi.org/10.1016/j.bioorg.2018.11.033>
- [8] Kondo, K., & Yamamura, Y. (2012). The Discovery of Samsca® (Tolvaptan): The First Oral Nonpeptide Vasopressin Receptor Antagonist. In *Case Studies in Modern Drug Discovery and Development*. <https://doi.org/10.1002/9781118219683.ch13>
- [9] Vullo, D., De Luca, V., Scozzafava, A., Carginale, V., Rossi, M., Supuran, C., & Capasso, C. (2013). The extremo- $\alpha$ -carbonic anhydrase from the thermophilic bacterium *Sulfurihydrogenibium azorense* is highly inhibited by sulfonamides. *Bioorganic & Medicinal Chemistry*, 21(15), 4521-4525. <https://doi.org/10.1016/j.bmc.2013.05.042>
- [10] Levin, J.I., Chen, J.M., Du, M.T., Nelson, F.C., Killar, L.M., Skala, S., & Skotnicki, J.S. (2002). Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group. *Bioorganic & Medicinal Chemistry Letters*, 12(8), 1199-1202. [https://doi.org/10.1016/S0960-894X\(02\)00136-1](https://doi.org/10.1016/S0960-894X(02)00136-1)

- [11] Kim, D.K., Lee, J.Y., Lee, N., Kim, J.S., Lee, S., Choi, J.Y., & Kim, T.K. (2001). Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. *Bioorganic & Medicinal Chemistry*, 9(11), 3013-3021.  
[https://doi.org/10.1016/S0968-0896\(01\)00200-0](https://doi.org/10.1016/S0968-0896(01)00200-0)
- [12] Hu, B., Ellingboe, J., Han, S., Largis, E., Lim, K., Malamas, M., & Wong, V. (2001). Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human  $\beta_3$  agonists. *Bioorganic & Medicinal Chemistry*, 9(8), 2045-2059.  
[https://doi.org/10.1016/S0968-0896\(01\)00114-6](https://doi.org/10.1016/S0968-0896(01)00114-6)
- [13] Ma, T., Fuld, A.D., Rigas, J.R., Hagey, A.E., Gordon, G.B., Dmitrovsky, E., & Dragnev, K.H. (2012). A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. *Chemotherapy*, 58(4), 321-329.  
<https://doi.org/10.1159/000343165>
- [14] Mondal, S., & Malakar, S. (2020). Synthesis of sulfonamide and their synthetic and therapeutic applications: Recent advances. *Tetrahedron*, 76, 131662.  
<https://doi.org/10.1016/j.tet.2020.131662>
- [15] Almarhoon, Z., Soliman, S.M., Ghabbour, H.A., & El-Faham, A. (2019). A facile and eco-friendly Method for the synthesis of sulfonamide and sulfonate carboxylic acid derivatives—X-ray structure, Hirshfeld analysis and spectroscopic characterizations. *Crystals*, 9(1), 35-40. <https://doi.org/10.3390/cryst9010035>
- [16] Ike, D.C., Abayeh, O.J., Ogali, R.E., Eruteya, O.C., & Umofia, E. (2018). Antibacterial activity of some selected substituted benzaldoximes. *Journal of Chemical Society Nigeria*, 43(3), 361-370.
- [17] Akujobi, C., Ogbulie, J.N., & Uchegbe, U.N. (2006). Antibacterial activities and preliminary phytochemical screening of four medicinal plants. *Journal of Applied Science*, 7(3), 4328-4338.